Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE)

• Published in: European heart journal supplements 2017-05, Vol.19 (Suppl D), p.D130-D150
• Main Authors: De Luca, Leonardo, Colivicchi, Furio, Gulizia, Michele Massimo, Pugliese, Francesco Rocco, Ruggieri, Maria Pia, Musumeci, Giuseppe, Cibinel, Gian Alfonso, Romeo, Francesco
• Format: Article
• Language: English
• ISSN: 1520-765X; 1554-2815
• DOI: 10.1093/eurheartj/sux013

Antiplatelet therapy is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS). Over the last years, several studies have evaluated old and new oral or intravenous antiplatelet agents in ACS patients. In particular, research was focused on assessing superiority of two novel platelet ADP P2Y12 receptor antagonists (i.e., prasugrel and ticagrelor) over clopidogrel. Several large randomized controlled trials have been undertaken in this setting and a wide variety of prespecified and analyses are available that evaluated the potential benefits of novel antiplatelet therapies in different subsets of patients with ACS. The aim of this document is to review recent data on the use of current antiplatelet agents for in-hospital treatment of ACS patients. In addition, in order to overcome increasing clinical challenges and implement effective therapeutic interventions, this document identifies all potential specific care pathway for ACS patients and accordingly proposes individualized therapeutic options.